Evidence map›Paper›PMID 40914890›Full record

ArticleFuture science OA2025

Immunoglobulin free light chain-κ in association with NT-proBNP levels after smoking cessation.

Maki Komiyama, Swati Mittal, Hajime Yamakage, Noriko Satoh-Asahara, Hiromichi Wada, Akihiro Yasoda, Masafumi Funamoto, Yasufumi Katanasaka, Yoichi Sunagawa, Tatsuya Morimoto and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Future science OA, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Maki KomiyamaClinical Research Institute, National Hospital Organization Kyoto Medical Center, Kyoto, Japan.
Swati MittalClinical Research Institute, National Hospital Organization Kyoto Medical Center, Kyoto, Japan.
Hajime YamakageClinical Research Institute, National Hospital Organization Kyoto Medical Center, Kyoto, Japan.
Noriko Satoh-AsaharaClinical Research Institute, National Hospital Organization Kyoto Medical Center, Kyoto, Japan.
Hiromichi WadaClinical Research Institute, National Hospital Organization Kyoto Medical Center, Kyoto, Japan.
Akihiro YasodaClinical Research Institute, National Hospital Organization Kyoto Medical Center, Kyoto, Japan.
Masafumi FunamotoClinical Research Institute, National Hospital Organization Kyoto Medical Center, Kyoto, Japan.
Yasufumi KatanasakaClinical Research Institute, National Hospital Organization Kyoto Medical Center, Kyoto, Japan.
Yoichi SunagawaClinical Research Institute, National Hospital Organization Kyoto Medical Center, Kyoto, Japan.
Tatsuya MorimotoClinical Research Institute, National Hospital Organization Kyoto Medical Center, Kyoto, Japan.
Yuko TakahashiClinical Research Institute, National Hospital Organization Kyoto Medical Center, Kyoto, Japan.
Takeo NakayamaDepartment of Health Informatics, Graduate School of Medicine & School of Public Health, Kyoto University, Japan.
Akira MatsumoriClinical Research Institute, National Hospital Organization Kyoto Medical Center, Kyoto, Japan.
Koji HasegawaClinical Research Institute, National Hospital Organization Kyoto Medical Center, Kyoto, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSmoking induces inflammation in the heart and intima layer of blood vessels by activating nuclear factor kappa B, which controls the transcription of immunoglobulin free light chain (FLC)-κ. FLC levels are indicative of higher mortality in the overall population and poorer prognoses in cardiovascular diseases. This study aimed to analyze the effect of smoking cessation (SC) on the levels of FLCs and markers of inflammation and heart failure. RESEARCH DESIGN AND

methodsThis study enrolled first visit smokers determined to quit smoking at our hospital. Levels of various clinical parameters, including inflammatory markers, such as FLC, were measured on their first clinic visit and after 3 months of successful SC.

resultsBody-mass-index (BMI) values significantly increased from baseline to 3 months after SC (n = 76,

conclusionsLevels of FLC-κ, a novel inflammatory and cardiovascular risk biomarker, decreased significantly after SC in association with NT-proBNP, suggesting the SC-induced reduction of cardiac load as well as a decrease in inflammation.

Indexed as

Biomarkerscardiologyclinical trialsinflammationsmokingsmoking cessation

Identifiers

PMID40914890
PMCPMC12416185

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.